Goldman starts coverage of Krystal Biotech stock at USD 441.00 target

Published on 10/08/2026 at 20:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 119.22 million. Krystal Biotech stock costs EUR 296.35 on October 8, 2026, plus 2.22 percent after EUR 289.90.

Key points in brief

Goldman Sachs started coverage of Krystal Biotech with a USD 441.00 price target on September 24, 2026.
Second-quarter 2026 revenue reached USD 119.22 million, while diluted earnings per share came to USD 1.79.
The Lang & Schwarz price was EUR 296.35 on October 8, 2026, up 2.22 percent from EUR 289.90.
Krystal Biotech stock is listed on Nasdaq under KRYS and operates in biotechnology.

KRYS, US5011471027, Illustration mit AI erstellt.

Krystal Biotech stock (ISIN US5011471027) was trading at EUR 296.35 at Lang & Schwarz on October 8, 2026, up 2.22 percent from EUR 289.90. Goldman Sachs started coverage with a USD 441.00 price target on September 24, 2026, according to TheFly.

Three dates frame the story

On August 3, 2026, Krystal Biotech reported second-quarter revenue of USD 119.22 million and diluted earnings per share of USD 1.79. MarketBeat said the earnings-per-share figure exceeded the USD 1.70 consensus, while revenue was below the USD 120.93 million estimate.

On September 10, 2026, management presented at the Cantor Fitzgerald Global Healthcare Conference. Investing.com reported trailing twelve-month revenue of USD 440.48 million and revenue growth of 22.63 percent.

On September 24, 2026, Goldman Sachs analyst Andrea Newkirk resumed coverage with a Buy rating and a USD 441.00 target, according to TheFly. The target is a separate valuation reference from the Lang & Schwarz euro quote and is not converted into euros.

What does the target mean?

The contrast is between a profitable commercial business and continued dependence on product execution. Second-quarter net income was USD 54.77 million in the finance statement, while revenue reached USD 119.22 million for the same period.

The earnings comparison is constructive but mixed: diluted earnings per share of USD 1.79 exceeded consensus by USD 0.09, whereas revenue missed consensus by USD 1.71 million. That split puts commercial momentum and pipeline progress alongside the need to expand revenue beyond the current product base.

Next reporting date

Zacks lists November 2, 2026 as the estimated date for Krystal Biotech's next earnings release and gives a consensus estimate of USD 1.91 per share for the quarter ending September 2026.

EUR 296.35 after the Xetra close

At Lang & Schwarz, Krystal Biotech was trading at EUR 296.35 on October 8, 2026, with a plus 2.22 percent change versus the prior close of EUR 289.90. The primary listing is Nasdaq, where the finance quote showed USD 330.71 on October 8, 2026, and a market capitalization of USD 9.7 billion.

The further course of trading is shown by the continuously updated real-time quote of Krystal Biotech stock.